Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of cabozantinib in hepatocellular carcinoma refractory to checkpoint inhibitors
KCT0005238Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Ipsen. Started Dec 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0005238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005238.